Charts

News

27 Jan, 2023
24 Jan, 2023
bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...
bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.
23 Jan, 2023
Credit Suisse raised the price target for Exelon Corporation (NASDAQ: EXC) from $42 to $46. Credit Suisse analyst Nicholas ...
22 Jan, 2023
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
19 Jan, 2023
Major Wall Street indices closed over 1.2% lower on Wednesday, dragged by renewed concerns of a recession as U.S. retail sales declined ...
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds from the public offering are expected be $120 million, before deducting underwriting discounts and commissions and offering expenses payable by bluebird and assuming no exercise of the underwriters’ option to purchase additional shares of common stock. All shares in the offering are to be sold by bluebird.
18 Jan, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 300 points on Wednesday. Here are some big stocks recording losses in ...
14:53
FinancialContent
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zomedica (ZOM) stock is on the rise Wednesday after the company signed a strategic restructuring agreement with Qorvo Biotechnologies. The post Why Is Zomedica (ZOM) Stock Up Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower by 10.0% to $6.55Wednesday morning after the company announced a proposed ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock is on the move Wednesday alongside positive results from its latest Phase 3 mRNA-1345 vaccine trial. The post Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
The Nasdaq looked poised for modest gains once again on Wednesday.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering. The post Why is Bluebird Bio (BLUE) Stock Down 9% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
Gainers Ontrak (NASDAQ:OTRK) stock increased by 44.3% to $0.83 during Wednesday's pre-market session. The market value of their ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offering may be completed. All shares in the offering are to be sold by bluebird.
09 Jan, 2023
bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at 7:30 a.m. PT.
07 Jan, 2023
These biotechs could crush the market, but there is more to the story.
06 Jan, 2023
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million.
05 Jan, 2023
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For ...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 7:30AM PT.
SOMERVILLE, Mass., January 05, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 7:30AM PT.
03 Jan, 2023
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing, collaborations and mergers and acquisitions, financial transactions, FDA regulations, compliance, manufacturing, and quality operations for organizations at all stages of development.
30 Dec, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
28 Dec, 2022
In this article, we will discuss the 15 most shorted stocks hedge funds are buying. You can skip our detailed overview and go directly to the 5 Most Shorted Stocks Hedge Funds Are Buying. The year 2022 has been a dynamic year for financial markets worldwide. The equity markets have come under selling pressure across […]
26 Dec, 2022
Several new drugs, most of them gene therapies, promise one-time treatments, but their price tags will test the health-insurance system.
24 Dec, 2022
This company has had a solid year, but there is still plenty of work ahead.
21 Dec, 2022
Investors need to pay close attention to bluebird bio (BLUE) stock based on the movements in the options market lately.
19 Dec, 2022
TheFDA removed its partial clinical holdonBluebird bio Inc's(NASDAQ: BLUE) study for patients under the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment. The post BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
Bluebird Bio Inc said on Monday that the U.S. health regulator had lifted a partial clinical hold on studies for its gene therapy to treat blood disorder sickle cell disease. The U.S. Food and Drug Administration's decision ends a year-long halt on future studies and a pause in enrollment for ongoing studies of lovo-cel after one case of persistent anemia in a patient. The move also signals a more favorable regulatory environment for cell and gene therapies after a spate of clinical holds by the regulator in the last few years, said SVB Securities analyst Mani Foroohar.
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel (lovo-cel) for sickle cell disease (SCD).
SOMERVILLE, Mass., December 19, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel (lovo-cel) for sickle cell disease (SCD).
13 Dec, 2022
Magenta Therapeutics Inc(NASDAQ: MGTA) highlightedupdated datafrom the ongoing MGTA-117 Phase 1/2 dose-escalation ...
12 Dec, 2022
The company looks set to continue its good momentum in the early part of next year.
10 Dec, 2022
Today new and updated data from bluebird bio inc.’s (NASDAQ: BLUE) gene therapy programs in beta-thalassemia and sickle cell disease were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The updated data demonstrate sustained treatment effect in patients treated with betibeglogene autotemcel (beti-cel) and lovotibeglogene autotemcel (lovo-cel) gene therapies through additional follow-up. Case studies of two patients diagnosed with persistent anemia following lovo-cel treatment were also presented. The ASH Annual Meeting is taking place December 10-13, 2022, in New Orleans and virtually.
06 Dec, 2022
These "exciting" companies aren't for everyone.
30 Nov, 2022
According to Benzinga Pro data, during Q3, bluebird bio (NASDAQ:BLUE) posted sales of $71 thousand. Earnings were up 23.59%, but ...
Bluebird Bio Inc(NASDAQ: BLUE) has agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV)for $102 ...
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.
23 Nov, 2022
UniQure N.V.'s(NASDAQ: QURE) partnerCSL Limited(OTC: CSLLY) hasreceived FDA approvalfor Hemgenix ...
20 Nov, 2022
The company could continue lagging the market for a while.
17 Nov, 2022
Both are lagging the market this year.
08 Nov, 2022
19:07
FinancialContent
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: Bullish Somewhat ...
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 66.5% to settle at $29.10 on Monday amid recent reports ...
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording ...
07 Nov, 2022
13:30
FinancialContent
bluebird bio (NASDAQ:BLUE) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need ...
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational progress.
02 Nov, 2022
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 31st Annual Credit Suisse Healthcare Conference, Tuesday, November 8, at 5:00 p.m. PT at the Terranea Resort, Rancho Palos Verdes, CA.
27 Oct, 2022
These two companies have performed almost equally poorly on the stock market in the past year.
26 Oct, 2022
18 Oct, 2022
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.
12 Oct, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
04 Oct, 2022
The near term looks good, but the long term might not.
03 Oct, 2022
Bluebird Bio Inc(NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the ...
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. SAI.TECH Global Corporation (NASDAQ: SAI) gained 43.4% ...
26 Sep, 2022
23 Aug, 2022

Related Articles